Developing Innovative Treatments for Neurological and Kidney Diseases

About Diamedica

DiaMedica (TSX-V:DMA; OTCQB:DMCAF) is a biopharmaceutical company focused on developing innovative treatments for neurological and kidney diseases where no current therapies are available.

About Diamedica

Product Candidates

DiaMedica’s lead clinical stage product, DM199, is a recombinant human tissue kallikrien (rhKLK-1) protein to treat acute ischemic stroke and diabetic kidney disease.

Investors

-- DMA
-- TSX Venture Exchange
--
-- DMCAF
-- OTCQB
--
View Investor Relations ›